Printer Friendly

THYMOSIN ALPHA 1 TO BE EVALUATED IN CLINICAL TRIAL IN MEXICO

 BETHESDA, Md., Jan. 7 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) and its licensee, SciClone Pharmaceuticals, Inc., have received approval from the FDA to export Thymosin alpha 1 to Mexico where it will be used in a clinical trial for the treatment of chronic hepatitis B. The principal investigator for the trial, which is scheduled to ultimately enroll 100 patients, is David Kershenobich, M.D. of the Instituto Nacional de la Nutricion in Mexico City. The protocol for the study is designed to meet the U.S. Food and Drug Administration (FDA) requirements for a phase III trial and will be conducted using Good Clinical Practices.
 "Drug for the clinical trial is available from inventory and will be shipped immediately," according to Vincent F. Simmon, president and CEO of Alpha 1 Biomedicals. "We are pleased that the export approval finally has been obtained. Alpha 1 expects to recognize revenue of about $300,000 during the first quarter of 1993 as a result of shipments of Thymosin alpha 1 to its licensees, primarily Sclavo, S.p.A. in Italy."
 Thymosin alpha 1 is manufactured by Alpha 1 Biomedicals in Foster City, Calif. Alpha 1 Biomedicals is currently sponsoring a multi-center phase III trial using Thymosin alpha 1 for the treatment of chronic hepatitis B in the United States. In addition, Sclavo is conducting a five-center phase III trial of Thymosin alpha 1 for the same indication in Italy. The results of the Italian trial should be available in mid- to late 1993 and the results from the U.S. trial are expected to be unblinded in the first half of 1994.
 Alpha 1 Biomedicals is also sponsoring a multi-center trial of Thymosin in combination with interferon for the treatment of chronic hepatitis C and recently announced a pilot trial using Thymosin alpha 1 in combination with PEG-IL2 and AZT for the treatment of AIDS.
 Alpha 1 Biomedicals, Inc. is a Bethesda, Md.-based biotechnology company engaged in the development of pharmaceutical products for the treatment of human immune disorders.
 -0- 1/7/93
 /CONTACT: Vincent F. Simmon, Ph.D., president and chief executive officer of Alpha 1 Biomedicals, Inc., 301-564-4400, or Anita Monteith- Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals, Inc./
 (ALBM)


CO: Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU:

PS-OS -- NY001 -- 2513 01/07/93 09:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1993
Words:393
Previous Article:SCIOS NOVA EXERCISES OPTION TO PURCHASE INTERESTS IN NOVA TECHNOLOGY LIMITED PARTNERSHIP
Next Article:SCHERING-PLOUGH AND CELLTECH IN AGREEMENT TO DEVELOP ANTIBODIES TO CYTOKINES
Topics:


Related Articles
NEW AIDS DRUG STUDY ANNOUNCED; STANFORD RESEARCHERS TO STUDY THYMOSIN alpha I
SCICLONE PHARMACEUTICALS ANNOUNCES APPROVAL TO BEGIN CLINICAL TRIALS IN JAPAN FOR THYMOSIN ALPHA 1
THYMOSIN ALPHA 1 COMBINATION STUDY SUGGESTS CD4+ RESPONSE
SCICLONE PHARMACEUTICALS BEGINS ASYMPTOMATIC HEPATITIS B TRIALS IN SINGAPORE
SCICLONE RESPONDS TO ALPHA 1 PRELIMINARY TRIAL REPORT
NOVEL ACTIN-SEQUESTERING PEPTIDE TO BE DEVELOPED BY ALPHA 1 BIOMEDICALS, INC.
SIGNIFICANT RESULTS IN HEPATITIS C STUDY WITH THYMOSIN ALPHA 1 AND INTERFERON ALPHA COMBINATION THERAPY
SCICLONE PHARMACEUTICALS REPORTS CONTINUED ENCOURAGING TREND IN TAIWAN CLINICAL TRIAL AND COMPLETION OF ANALYSIS OF U.S. CLINICAL TRIAL
ALPHA 1 BIOMEDICALS SUSPENDS DEVELOPMENT OF CYSTIC FIBROSIS DRUG
Hepatology Article Points to Promise of Thymosin Alpha 1 as a Therapy for Hepatitis C

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters